Page 57 - 86_02

ANALES
RANF
www.analesranf.com
DOX Doxorrubicina
ee eficacia de encapsulación
Ic Índice de combinación
mcA membrana corioalantoidea de embriones de
PLGA pollo fecundados
PLGA-Nps Poli-láctico-co-glicólico
PtX Nanopartículas blancas
PVA Paclitaxel
Alcohol polivinílico
7. AGRADECIMIENTOS
Los autores agradecen al ministerio de educación, cultura
y Deporte la concesión de la ayuda para contratos predoctorales de
Formación del Profesorado universitario a Ana Isabel Fraguas sán-
chez (referencia FPu 14/06441).
8. REFERENCIAS
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global
cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA: a cancer journal for cli-
nicians. 2018;68(6):394-424.
2. Mizushima T, Miyamoto H. The Role of Androgen Receptor Signaling
in Ovarian Cancer. Cells. 2019;8(2).
3. Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-
Acevedo M, et al. Epigenetic therapy for ovarian cancer: promise and
progress. Clinical epigenetics. 2019;11(1):7.
4. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht
K, Berchuck A, et al. NCCN Guidelines Insights: Ovarian Cancer, Version
1.2019. J Natl Compr Canc Netw. 2019;17(8):896-909.
5. Tsibulak I, Zeimet AG, Marth C. Hopes and failures in front-line ovarian
cancer therapy. Crit Rev Oncol Hematol. 2019;143:14-9.
6. Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, et
al. Ovarian cancer: Current status and strategies for improving thera-
peutic outcomes. Cancer medicine. 2019.
7. Livshits Z, Rao RB, Smith SW. An approach to chemotherapy-associated
toxicity. Emerg Med Clin North Am. 2014;32(1):167-203.
8. Kalaydina RV, Bajwa K, Qorri B, Decarlo A, Szewczuk MR. Recent ad-
vances in "smart" delivery systems for extended drug release in cancer
therapy. Int J Nanomedicine. 2018;13:4727-45.
9. Fraguas-Sanchez AI, Torres-Suarez AI. Medical Use of Cannabinoids.
Drugs. 2018;78(16):1665-703.
10. Pisanti S, Bifulco M. Medical Cannabis: A plurimillennial history of an
evergreen. Journal of cellular physiology. 2018.
11. !!! INVALID CITATION !!! {Fraguas-Sanchez, 2018 #3}.
12. Daris B, Tancer Verboten M, Knez Z, Ferk P. Cannabinoids in cancer
treatment: Therapeutic potential and legislation. Bosnian journal of
basic medical sciences. 2019;19(1):14-23.
13. Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, et
al. Cannabidiol: State of the art and new challenges for therapeutic
applications. Pharmacology & therapeutics. 2017;175:133-50.
14. Cohen K, Weizman A, Weinstein A. Positive and Negative Effects of
Cannabis and Cannabinoids on Health. Clinical pharmacology and the-
rapeutics. 2019.
15. McAllister SD, Soroceanu L, Desprez PY. The Antitumor Activity of Plant-
Derived Non-Psychoactive Cannabinoids. Journal of neuroimmune
pharmacology : the official journal of the Society on NeuroImmune
Pharmacology. 2015;10(2):255-67.
16. Likar R, Nahler G. The use of cannabis in supportive care and treatment
of brain tumor. Neurooncol Pract. 2017;4(3):151-60.
17. Kiskova T, Mungenast F, Suvakova M, Jager W, Thalhammer T. Future
Aspects for Cannabinoids in Breast Cancer Therapy. Int J Mol Sci.
2019;20(7).
18. Pagano E, Borrelli F. Targeting cannabinoid receptors in gastrointestinal
cancers for therapeutic uses: current status and future perspectives. Ex-
pert Rev Gastroenterol Hepatol. 2017;11(10):871-3.
19. Messalli EM, Grauso F, Luise R, Angelini A, Rossiello R. Cannabinoid
receptor type 1 immunoreactivity and disease severity in human epi-
thelial ovarian tumors. American journal of obstetrics and gynecology.
2014;211(3):234.e1-6.
20. Holland ML, Panetta JA, Hoskins JM, Bebawy M, Roufogalis BD, Allen
JD, et al. The effects of cannabinoids on P-glycoprotein transport and
expression in multidrug resistant cells. Biochemical pharmacology.
2006;71(8):1146-54.
21. Scott KA, Dalgleish AG, Liu WM. Anticancer effects of phytocannabinoids
used with chemotherapy in leukaemia cells can be improved by altering
the sequence of their administration. International journal of oncology.
2017;51(1):369-77.
22. Lopez-Valero I, Saiz-Ladera C, Torres S, Hernandez-Tiedra S, Garcia-
Taboada E, Rodriguez-Fornes F, et al. Targeting Glioma Initiating Cells
with A combined therapy of cannabinoids and temozolomide. Bioche-
mical pharmacology. 2018;157:266-74.
23. Lopez-Valero I, Torres S, Salazar-Roa M, Garcia-Taboada E, Hernan-
dez-Tiedra S, Guzman M, et al. Optimization of a preclinical therapy
of cannabinoids in combination with temozolomide against glioma.
Biochemical pharmacology. 2018;157:275-84.
24. Viudez-Martinez A, Garcia-Gutierrez MS, Navarron CM, Morales-Calero
MI, Navarrete F, Torres-Suarez AI, et al. Cannabidiol reduces ethanol
consumption, motivation and relapse in mice. Addiction biology.
2018;23(1):154-64.
25. Fraguas-Sanchez AI, Martin-Sabroso C, Fernandez-Carballido A, To-
rres-Suarez AI. Current status of nanomedicine in the chemotherapy of
breast cancer. Cancer chemotherapy and pharmacology.
Quimioterapia nanométrica a base de cannabinoides 147
para el tratamiento de tumores ginecológicos
Ana I. Fraguas , Ana I. Torres Suárez, et al
An Real Acad Farm Vol. 86. Nº 2 (2020) · pp. 133-150